This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot
The Zacks Analyst Blog Highlights: Chevron, Merck, Walgreens Boots, FedEx and Loews
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Merck, Walgreens Boots, FedEx and Loews
Walgreens Gains on Strategic Deals, Margin Pressure Remains
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.
Company News for Jun 28, 2019
by Zacks Equity Research
Companies in the news are: WBA, KBH, LYFT and CAG
Dow 30 Stock Roundup: Nike Earnings Disappoint, Walgreens Boots Margins Drop
by Swarup Gupta
The index suffered a disappointing week, declining over three straight trading sessions
Top Research Reports for Chevron, Merck & Walgreens Boots
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Merck (MRK) and Walgreens Boots (WBA).
Will Amazon (AMZN) be Rite-Aid's (RAD) Bandage?
by Mitchell Moore
Rite Aid Corporation (RAD) posted its Q1 2020 earnings results on Wednesday, June 26, after market close. This report was disappointing with an adjusted loss of -$0.14 per share, a steep dive from our zacks Consensus Estimate of +$0.02.
Rite Aid (RAD) Incurs Loss in Q1, Revenues Decline Y/Y
by Zacks Equity Research
Rite Aid (RAD) incurs loss in first-quarter fiscal 2020. However, it reaffirms outlook for the fiscal year.
Walgreens Boots (WBA) Q3 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division gains traction from comparable prescription volume growth and a sturdy retail prescription market.
Walgreens Boots Alliance (WBA) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of 3.52% and 0.16%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Pharmacy International Hit Walgreens (WBA) Q3 Earnings?
by Zacks Equity Research
Challenging market conditions, especially in retail, causes a slowdown in the Retail Pharmacy International division at Walgreens Boots (WBA).
Analysts Estimate Walgreens Boots Alliance (WBA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Alphabet, Amazon, Apple, Sanofi and Walgreens
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Amazon, Apple, Sanofi and Walgreens
Alphabet's Healthcare Push Gains Steam: Others Brace Up
by Shilpa Mete
Alphabet's (GOOGL) Google's partnership with Sanofi provides it a competitive edge in the healthcare sector.
Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $52.80 in the latest trading session, marking a -0.02% move from the prior day.
Buy Kroger (KR) Stock Before Q1 Earnings as Amazon-Inspired Grocery Delivery Expands?
by Benjamin Rains
Overall, the first quarter has been relatively strong for retailers, so let's look at what investors should expect from Kroger to see if they should consider buying KR stock heading into its Q1 earnings release.
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $52.12, marking a -1.44% move from the previous day.
The Zacks Analyst Blog Highlights: Oracle, Eli Lilly, Mondelez, Walgreens and Southwest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Eli Lilly, Mondelez, Walgreens and Southwest
Top Analyst Reports for Oracle, Eli Lilly & Mondelez
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Eli Lilly (LLY) and Mondelez (MDLZ).
Do Hemp Stocks Stand to Gain From a Weed-Liberal Illinois?
by Nitish Marwah
The marijuana legislation in Illinois would allow any resident of the state above the age of 21 to possess the novelty item.
Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $50.98, marking a +0.35% move from the previous day.
Walgreens' Weak Market Trends a Woe, Strategic Deals a Boon
by Zacks Equity Research
Walgreens Boots (WBA) is diligently trying to redress specific areas of operational weakness and enhancing its managerial skills for a better operating performance.
The Zacks Analyst Blog Highlights: General Electric, Anthem, Northrop Grumman, Walgreens and Honda
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Electric, Anthem, Northrop Grumman, Walgreens and Honda
The Geo Group, Vista Outdoor, CVS and Walgreens Boots Alliance highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
The Geo Group, Vista Outdoor, CVS and Walgreens Boots Alliance highlighted as Zacks Bull and Bear of the Day
Buy CVS Health (CVS) Stock After Optimistic Investor Day 2019?
by Zachary Stutler
CVS (CVS) stock jumped over 2% upon opening Tuesday morning and ended the day at $54.62, a 2.3% gain on the day. Confidence in the company???s future growth grew when it made multiple announcements regarding future earnings and projects at its investor day 2019 event.